HC Wainwright Brokers Raise Earnings Estimates for VYGR

Key Points

• HC Wainwright raised Voyager Therapeutics’ EPS forecasts, including improving its Q3 2026 loss estimate to $0.29 per share from $0.39 and its FY2026 loss estimate to $1.32 from $1.61. The firm maintained a “Buy” rating.
• Analyst sentiment is mixed but leans positive: Voyager has an average “Moderate Buy” rating and a $16.50 price target, although Weiss Ratings and Wall Street Zen rate the stock “Sell.”
• Voyager remains unprofitable, with losses projected through 2030. In its latest quarter, the company reported a $0.40-per-share loss—better than estimates—but revenue of $3.17 million fell short of the $4.52 million consensus.

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Investment analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for Voyager Therapeutics in a research note issued to investors on Monday, August 10th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.29) per share for the quarter, up from their previous forecast of ($0.39). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Voyager Therapeutics' current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Voyager Therapeutics' Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($1.32) EPS, Q1 2027 earnings at ($0.26) EPS, Q2 2027 earnings at ($0.26) EPS, Q3 2027 earnings at ($0.27) EPS, Q4 2027 earnings at ($0.25) EPS, FY2027 earnings at ($1.06) EPS, FY2028 earnings at ($1.17) EPS, FY2029 earnings at ($0.98) EPS and FY2030 earnings at ($0.55) EPS.

Several other analysts also recently weighed in on VYGR. Weiss Ratings reissued a "sell (d-)" rating on shares of Voyager Therapeutics in a research note on Monday, July 13th. Wall Street Zen cut Voyager Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Voyager Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $16.50.

Voyager Therapeutics Stock Performance

VYGR stock opened at $3.20 on Wednesday. Voyager Therapeutics has a 52 week low of $2.93 and a 52 week high of $5.55. The firm's fifty day moving average is $3.38 and its 200 day moving average is $3.73. The firm has a market cap of $193.35 million, a P/E ratio of -1.78 and a beta of 1.31.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.48) by $0.08. The firm had revenue of $3.17 million during the quarter, compared to analyst estimates of $4.52 million. Voyager Therapeutics had a negative net margin of 312.63% and a negative return on equity of 54.82%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. EcoR1 Capital LLC raised its holdings in Voyager Therapeutics by 497.2% during the 4th quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company's stock valued at $15,731,000 after buying an additional 3,332,544 shares during the last quarter. Altshuler Shaham Ltd bought a new stake in Voyager Therapeutics in the 4th quarter worth $801,000. Renaissance Technologies LLC raised its stake in shares of Voyager Therapeutics by 95.0% during the first quarter. Renaissance Technologies LLC now owns 578,024 shares of the company's stock valued at $2,231,000 after acquiring an additional 281,574 shares during the last quarter. Quantinno Capital Management LP raised its stake in shares of Voyager Therapeutics by 14.1% during the first quarter. Quantinno Capital Management LP now owns 35,703 shares of the company's stock valued at $138,000 after acquiring an additional 4,405 shares during the last quarter. Finally, Sei Investments Co. purchased a new stake in shares of Voyager Therapeutics during the first quarter worth about $112,000. Institutional investors own 48.03% of the company's stock.

Key Stories Impacting Voyager Therapeutics

Here are the key news stories impacting Voyager Therapeutics this week:

• Positive Sentiment: HC Wainwright raised EPS forecasts across multiple periods. The firm improved its estimates for Q3 and Q4 2026, every quarter of 2027, and fiscal years 2026 through 2030. Notably, its FY2026 loss estimate improved to $1.32 per share from $1.61, FY2027 to $1.06 from $1.18, FY2028 to $1.17 from $1.63, FY2029 to $0.98 from $1.38, and FY2030 to $0.55 from $0.94. Although Voyager is still expected to report losses, the revisions suggest HC Wainwright sees a less severe earnings trajectory than previously anticipated.
• Positive Sentiment: HC Wainwright maintained its “Buy” rating. The repeated estimate increases and reaffirmed bullish rating provide a favorable sentiment catalyst for VYGR, particularly for a small-cap biotechnology company whose valuation is sensitive to analyst expectations. HC Wainwright Reaffirms Buy Rating for Voyager Therapeutics
• Neutral Sentiment: Short-interest data offers little trading signal. Reported short interest was zero shares as of August 11, unchanged from the prior period, with a zero-day short-interest ratio. This indicates no measurable short-covering or elevated bearish positioning to materially influence the shares.
• Negative Sentiment: Voyager remains unprofitable. HC Wainwright’s revised forecasts still call for losses through 2030, while the consensus current-year estimate remains a $1.39-per-share loss. The company’s limited revenue base and ongoing cash-burn risk remain important counterweights to the improved estimates.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company's core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm's pipeline includes several AAV-based candidates in preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source